Recent News

• 06.12.2025 - Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
• 05.15.2025 - Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
• 05.08.2025 - Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
• 04.17.2025 - Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq
• 04.03.2025 - Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
• 03.13.2025 - Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
• 03.04.2025 - Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Recent Filings

• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - 8-K Current report
• 05.08.2025 - EX-99.1 EX-99.1
• 04.17.2025 - 8-K Current report
• 04.17.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.24.2025 - 4/A Statement of changes in beneficial ownership of securities
• 03.13.2025 - 8-K Current report
• 03.13.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.13.2025 - EX-99.1 EX-99.1
• 03.04.2025 - 8-K Current report